{
  "id": "everyday#risk_safety_eab74ed6",
  "title_en": "General — Risk Safety",
  "title_vi": "General — Nguy cơ An toàn",
  "text_en": "Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders 139. Karyotaki E, Araya R, Kessler RC, Waqas A, 146. The health and social effects of nonmedical Bhana A, Rahman A et al. Association of task- cannabis use. Geneva: World Health Organization; shared psychological interventions with 2016 (https://iris.who.int/handle/10665/251056). depression outcomes in low- and middle-income 147. World Health Organization, United Nations Office countries: a systematic review and individual on Drugs and Crime. International standards patient data meta-analysis. JAMA Psychiatry. for the treatment of drug use disorders: revised 2022;79(5):430–43 (https://doi.org/10.1001/ edition incorporating results of field-testing. jamapsychiatry.2022.0301). Geneva: World Health Organization; 2020 (https:// 140. Cuijpers P, Noma H, Karyotaki E, Vinkers CH, apps.who.int/iris/handle/10665/331635). Cipriani A, Furukawa TA. A network meta- 148. Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin analysis of the effects of psychotherapies, FR, Fidalgo TM. Prescription psychostimulants pharmacotherapies and their combination in the for the treatment of stimulant use disorder: treatment of adult depression. World Psychiatry. a systematic review and meta-analysis. 2020;19(1):92–107 (https://doi.org/10.1002/ Psychopharmacology. 2020;237(8):2233–55 wps.20701). (https://doi.org/10.1007/s00213-020-05563-3). 141. Furukawa TA, Shinohara K, Sahker E, Karyotaki 149. Nourredine M, Jurek L, Angerville B, Longuet Y, de E, Miguel C, Ciharova M et al. Initial treatment Ternay J, Derveaux A et al. Use of topiramate in choices to achieve sustained response in major the spectrum of addictive and eating disorders: depression: a systematic review and network a systematic review comparing treatment meta-analysis. World Psychiatry. 2021;20(3):387– schemes, efficacy, and safety features. CNS Drugs. 96 (https://doi.org/10.1002/wps.20906). 2021;35(2):177–213 (https://doi.org/10.1007/ 142. Chou R, Dana T, Blazina I, Grusing S, Fu R, s40263-020-00780-y). Bougatsos C. Interventions for unhealthy drug 150. Chan B, Freeman M, Ayers C, Korthuis PT, use – supplemental report: a systematic review for Paynter R, Kondo K et al. A systematic review the U.S. Preventive Services Task Force. Evidence and meta-analysis of medications for stimulant synthesis No. 187. Rockville (MD): Agency for use disorders in patients with co-occurring Healthcare Research and Quality; 2020 (https:// opioid use disorders. Drug Alcohol Depend. www.ncbi.nlm.nih.gov/books/NBK558205/). 2020;216:108193 (https://doi.org/10.1016/j. 143. World drug report 2022. Vienna: United Nations drugalcdep.2020.108193). Office on Drugs and Crime; 2022 (https://www. 151. Buchholz J, Saxon AJ. Medications to treat unodc.org/unodc/data-and-analysis/world-drug- cocaine use disorders: current options. Curr report-2022.html). Opin Psychiatry. 2019;32(4):275–81 (https://doi. 144. Cannabis use disorders – level 4 cause. Seattle org/10.1097/YCO.0000000000000518). (WA): The Institute for Health Metrics and 152. Chan B, Kondo K, Freeman M, Ayers C, Evaluation; 2019 (https://www.healthdata.org/ Montgomery J, Kansagara D. Pharmacotherapy results/gbd_summaries/2019/cannabis-use- for cocaine use disorder – a systematic disorders-level-4-cause, accessed 20 October review and meta-analysis. J Gen Intern Med. 2023). 2019;34(12):2858–73 (https://doi.org/10.1007/ 145. Degenhardt L, Ferrari AJ, Calabria B, Hall s11606-019-05074-8). WD, Norman RE, McGrath J et al. The global 153. Fluyau D, Revadigar N, Pierre CG. Systematic epidemiology and contribution of cannabis review and meta-analysis: treatment of substance use and dependence to the global burden of use disorder in attention deficit hyperactivity disease: results from the GBD 2010",
  "gloss_vi": "Mental health gap action programme (mhgap) guideline for mental, neurological and substance use disorders 139. karyotaki e, araya r, kessler rc, waqas a, 146.",
  "source": "Everyday Essentials",
  "url": "",
  "lang": "en",
  "axes": {
    "type": [
      "clinical",
      "everyday"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "risk_safety"
    ],
    "life_topics": [
      "work"
    ],
    "advice_section": [],
    "audience": [],
    "risk_band": "low"
  },
  "index_text": "General — Risk Safety General — Nguy cơ An toàn Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders 139. Karyotaki E, Araya R, Kessler RC, Waqas A, 146. The health and social effects of nonmedical Bhana A, Rahman A et al. Association of task- cannabis use. Geneva: World Health Organization; shared psychological interventions with 2016 (https://iris.who.int/handle/10665/251056). depression outcomes in low- and middle-income 147. World Health Organization, United Nations Office countries: a systematic review and individual on Drugs and Crime. International standards patient data meta-analysis. JAMA Psychiatry. for the treatment of drug use disorders: revised 2022;79(5):430–43 (https://doi.org/10.1001/ edition incorporating results of field-testing. jamapsychiatry.2022.0301). Geneva: World Health Organization; 2020 (https:// 140. Cuijpers P, Noma H, Karyotaki E, Vinkers CH, apps.who.int/iris/handle/10665/331635). Cipriani A, Furukawa TA. A network meta- 148. Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin analysis of the effects of psychotherapies, FR, Fidalgo TM. Prescription psychostimulants pharmacotherapies and their combination in the for the treatment of stimulant use disorder: treatment of adult depression. World Psychiatry. a systematic review and meta-analysis. 2020;19(1):92–107 (https://doi.org/10.1002/ Psychopharmacology. 2020;237(8):2233–55 wps.20701). (https://doi.org/10.1007/s00213-020-05563-3). 141. Furukawa TA, Shinohara K, Sahker E, Karyotaki 149. Nourredine M, Jurek L, Angerville B, Longuet Y, de E, Miguel C, Ciharova M et al. Initial treatment Ternay J, Derveaux A et al. Use of topiramate in choices to achieve sustained response in major the spectrum of addictive and eating disorders: depression: a systematic review and network a systematic review comparing treatment meta-analysis. World Psychiatry. 2021;20(3):387– schemes, efficacy, and safety features. CNS Drugs. 96 (https://doi.org/10.1002/wps.20906). 2021;35(2):177–213 (https://doi.org/10.1007/ 142. Chou R, Dana T, Blazina I, Grusing S, Fu R, s40263-020-00780-y). Bougatsos C. Interventions for unhealthy drug 150. Chan B, Freeman M, Ayers C, Korthuis PT, use – supplemental report: a systematic review for Paynter R, Kondo K et al. A systematic review the U.S. Preventive Services Task Force. Evidence and meta-analysis of medications for stimulant synthesis No. 187. Rockville (MD): Agency for use disorders in patients with co-occurring Healthcare Research and Quality; 2020 (https:// opioid use disorders. Drug Alcohol Depend. www.ncbi.nlm.nih.gov/books/NBK558205/). 2020;216:108193 (https://doi.org/10.1016/j. 143. World drug report 2022. Vienna: United Nations drugalcdep.2020.108193). Office on Drugs and Crime; 2022 (https://www. 151. Buchholz J, Saxon AJ. Medications to treat unodc.org/unodc/data-and-analysis/world-drug- cocaine use disorders: current options. Curr report-2022.html). Opin Psychiatry. 2019;32(4):275–81 (https://doi. 144. Cannabis use disorders – level 4 cause. Seattle org/10.1097/YCO.0000000000000518). (WA): The Institute for Health Metrics and 152. Chan B, Kondo K, Freeman M, Ayers C, Evaluation; 2019 (https://www.healthdata.org/ Montgomery J, Kansagara D. Pharmacotherapy results/gbd_summaries/2019/cannabis-use- for cocaine use disorder – a systematic disorders-level-4-cause, accessed 20 October review and meta-analysis. J Gen Intern Med. 2023). 2019;34(12):2858–73 (https://doi.org/10.1007/ 145. Degenhardt L, Ferrari AJ, Calabria B, Hall s11606-019-05074-8). WD, Norman RE, McGrath J et al. The global 153. Fluyau D, Revadigar N, Pierre CG. Systematic epidemiology and contribution of cannabis review and meta-analysis: treatment of substance use and dependence to the global burden of use disorder in attention deficit hyperactivity disease: results from the GBD 2010 Mental health gap action programme (mhgap) guideline for mental, neurological and substance use disorders 139. karyotaki e, araya r, kessler rc, waqas a, 146."
}